StockVS

Phaos Technology Holdings (Caym (POAS) Analyse boursière

Santé

Phaos Technology Holdings (Caym

$2.60

$-0.02 (-0.76%)

Dernière mise à jour : 26 mai 2026

Historique des Prix

Analyse

Présentation de l'entreprise

Phaos Technology Holdings (Cayman) Limited, via its subsidiary Phaos Technology Pte. Ltd., specializes in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products within Singapore. The company operates in the healthcare sector, specifically within the medical devices industry, focusing on the development of Optonano which facilitates the viewing of live and still imagery. Phaos Technology Holdings (Caym) currently maintains a market capitalization of $21.93M and employs 25 individuals to support its operations. The annual revenue reported over the trailing twelve months is $167,707, figures that reflect a very small enterprise with limited operational scale relative to established industry peers. The combination of a market cap of $21.93M and revenue of $167,707 indicates that the company occupies a niche position with minimal market penetration, suggesting it is in an early-stage development or post-funding phase where valuation is driven more by potential technology adoption than by current cash flow generation.

Santé financière

The financial statements for the trailing twelve months show a revenue of $167,707, a net income of $-5,137,064, and an EBITDA of $-3,869,313. The substantial gap between the positive revenue of $167,707 and the significant net loss of $-5,137,064 reveals a cost structure where operating expenses and costs of goods sold vastly exceed the total revenue generated, indicating severe inefficiency or heavy upfront capital expenditure not yet recovered. The company reports a free cash flow of $-1,657,362, which signifies a negative financial flexibility and an inability to fund operations or growth initiatives without external capital injections. Profitability metrics are severely compromised, with a gross margin of 22.1%, an operating margin of -1897.8%, and a profit margin of 0.0%, all of which indicate that the company is not generating profit from sales and is operating at a significant loss on every dollar of revenue. Regarding the balance sheet, the company holds $177,660 in cash against $3.26M in debt, creating a situation where liabilities significantly outweigh liquid assets, while the debt-to-equity ratio is listed as N/A, preventing a standard leverage assessment but highlighting the reliance on external financing. The current ratio stands at 0.40, a figure that indicates the company possesses less than half the current assets necessary to cover its short-term liabilities, pointing to acute liquidity risks. Return on Equity is -1073.1% and Return on Assets is -71.2%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate returns.

Évaluation de la valorisation

Valuation multiples for Phaos Technology Holdings (Caym) are distorted by its lack of profitability, with a trailing P/E ratio (TTM) of N/A and a forward P/E of N/A. The absence of these standard earnings-based multiples implies that the market cannot value the stock based on current or expected earnings per share, as the earnings are negative. The price-to-book ratio is -27.23, a negative figure that indicates the market capitalization is significantly below the company's net asset value, often seen in distressed or loss-making entities rather than those commanding a premium. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 130.77 and an EV/EBITDA of -11.44, suggesting that the market price is extremely high relative to the minimal sales volume and that the enterprise value is negative relative to EBITDA due to losses. The stock's price volatility is historically contained between a 52-week high of $7.39 and a 52-week low of $0.53, meaning the current trading price sits somewhere within this range, reflecting extreme price instability typical of micro-cap speculative stocks. The beta is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market index, as the standard deviation of returns is likely too high or the data window insufficient for calculation.

Growth & Income

The company demonstrates a revenue growth (YoY) of -93.1% and an earnings growth (YoY) of N/A, indicating a dramatic contraction in sales activity over the past year. Since earnings growth is N/A due to negative earnings, there is no earnings growth to compare against revenue decline, but the negative revenue growth confirms a shrinking top line that exacerbates the loss position. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all its capital internally rather than distributing income to shareholders. Given the lack of positive earnings and the significant cash burn, the company is not in a position to pay dividends and instead must focus on retaining cash to sustain operations, though the negative free cash flow suggests even this is challenging. The overall growth and income profile is characterized by a severe decline in revenue, negative returns on capital, and a total absence of dividend income, presenting a high-risk scenario for investors seeking capital appreciation or income generation.

Comparaison avec les pairs

Phaos Technology Holdings (Caym (POAS) opère dans le secteur Dispositifs Médicaux. Voici comment il se compare à ses pairs les plus proches par capitalisation boursière :

Entreprise Ticker Cap. Boursière Ratio P/E
Phaos Technology Holdings (Caym POAS $43.09M N/A
Abbott Laboratories ABT $150.96B 24.3
Stryker Corporation SYK $119.99B 36.2
Medtronic plc MDT $99.63B 21.7

Le ratio P/E moyen du secteur Dispositifs Médicaux est de 60.2x. Phaos Technology Holdings (Caym se négocie à un P/E de N/A.

Cette analyse est générée par IA à titre informatif uniquement et ne constitue pas un conseil financier. Les données peuvent être retardées ou inexactes. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.

À propos de Phaos Technology Holdings (Caym

Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore. The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation. It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization. In addition, the company offers software. The company serves manufacturing companies; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.

La description de l'entreprise est affichée en anglais.

Visiter le site →

Statistiques Clés

Capitalisation
$43.09M
Ratio P/E
N/A
Plus Haut 52 Sem.
$7.39
Plus Bas 52 Sem.
$0.53
Volume Moyen
732.53K

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Bourse
AMEX
Pays
Singapore
Employés
25